Conditional ablation of <i>Ybx1</i> leads to a reduction in cortical progenitor cell pool and a decrease in cortical thickness. حسب Jian Zhang (1682)

Inhibition of LDHA leads to decreased ATP, reduced AKT phosphorylation, and enhanced chemotherapy sensitivity to LBP in A549 and NCL-H1975 cells. حسب Siyu Yuan (7425719)

General procedure for the synthesis of A and A-c1. حسب Xueqin lu (22250795)

The significant decrease in GLT-1 levels observed in the nucleus accumbens of rats that had consumed morphine for fifty-six days was completely reversed by the co-administration of... حسب María Elena Quintanilla (8068691)

The Laboratory Animal Flow Diagram. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

¹H NMR spectra for kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

¹³C NMR spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

The structures of T3 and Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

Synthesis process of Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

ESI-HRMS spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. حسب Xueqin lu (22250795)

General procedure for the synthesis of B. حسب Xueqin lu (22250795)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. حسب Xueqin lu (22250795)

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. حسب Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. حسب Xueqin lu (22250795)

Kylo-0603’s EC50 & tissue levels. حسب Xueqin lu (22250795)

DIO Mice Liver Staining. حسب Xueqin lu (22250795)

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. حسب Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). حسب Xueqin lu (22250795)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. حسب Xueqin lu (22250795)